Live from the NIH registry
Studies recruiting near Kennewick right now
Top 25 of 54 recruiting studies, sorted by proximity — each links to its official registry page
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
Phase 3
Interventional 560 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Regeneron Pharmaceuticals
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Wake Forest University Health Sciences
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Phase 3
Interventional 230 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Hoffmann-La Roche
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Phase 3
Interventional 1,400 participants sought
Kadlec Clinic Hematology and Onco — Kennewick, Washington (2.0 mi)
· Sponsor: Novartis Pharmaceuticals
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Breast Cancer
Phase 3
Interventional 420 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Hoffmann-La Roche
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2
Interventional 189 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Malignant Solid Neoplasm
N/A
Interventional 760 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
Central Line Associated Blood Stream Infections (CLABSI)
N/A
Interventional 17,800 participants sought
Kadlec Regional Medical Center — Richland, Washington (8.1 mi)
· Sponsor: Swedish Medical Center
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
N/A
Interventional 739 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Family Communications After Genetic Testing
Colon Adenocarcinoma, Colorectal Adenocarcinoma
N/A
Interventional 4,186 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: NRG Oncology
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3
Interventional 94 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder
N/A
Observational 2,240 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Phase 3
Interventional 1,264 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Eli Lilly and Company
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
N/A
Observational 2,000 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Multiple conditions
N/A
Observational 2,000 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Phase 2
Interventional 141 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Multiple conditions
Phase 3
Interventional 1,780 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Children's Oncology Group
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Phase 2
Interventional 84 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)